SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-001977
Filing Date
2021-10-01
Accepted
2021-10-01 16:59:36
Documents
12
Period of Report
2021-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K janx-20211001.htm   iXBRL 8-K 51136
  Complete submission text file 0000950170-21-001977.txt   177206

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20211001_lab.xml EX-101.LAB 14743
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20211001_pre.xml EX-101.PRE 11865
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20211001.xsd EX-101.SCH 2479
5 EXTRACTED XBRL INSTANCE DOCUMENT janx-20211001_htm.xml XML 5110
Mailing Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037
Business Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037 858-750-4700
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 211299716
SIC: 2834 Pharmaceutical Preparations